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Abstract
Background: Pericarditis is the most common disease affecting the pericardium of the heart. It is
inflammation of the fibrous pericardial sac surrounding the heart. Five percent of emergency department
visits with chest pain not relating to myocardial infarction are attributed to pericarditis. Evidence shows 80%
of cases in developed nations are idiopathic or post-viral in nature. Treatment has consisted of NSAIDS and
glucocorticoids as first line therapy. Colchicine is an anti-inflammatory medication that has long been used in
the therapy of gout arthritis and other rheumatologic complaints worldwide. It has been proposed that the
anti-inflammatory profile occurring within joints can apply to the pericardium of the heart. The purpose of
this study is to evaluate how efficacious colchicine is when added to traditional therapy in the treatment of
pericarditis.
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL, and Pub-Med using
keywords: pericarditis and colchicine. Articles with primary data evaluating the use of colchicine in treating
pericarditis were included. These relevant articles were assessed for quality using the Grading of
Recommendations, Assessment, Development and Evaluation (GRADE)
Results: Three studies met the inclusion criteria for this systematic review. A randomized, double blind,
placebo-controlled study investigating colchicine and the treatment of pericarditis demonstrated a reduction
in recurrence rate, symptom persistence, and the need for hospitalization. A second randomized, double
blind, placebo-controlled study demonstrated a reduction in disease recurrence, symptom persistence, and
hospitalization related to the disease. Another randomized, open-label trial evaluating colchicine therapy in
treating acute pericarditis demonstrated a decrease in recurrence rate and symptom persistence.
Conclusion: Colchicine when treating pericarditis was demonstrated to reduce disease recurrence, lessen
symptom persistence, and limit the need for hospitalization. The safety and efficacy has been evaluated
through multiple trials and deemed superior to standard therapy alone. The overall quality of the studies
reviewed is moderate based on the GRADE criteria. A weak recommendation for the off-label use of
colchicine in the treatment plan of pericarditis can be given at this time based on the available data.
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Abstract 
 
Background: Pericarditis is the most common disease affecting the pericardium of the 
heart. It is inflammation of the fibrous pericardial sac surrounding the heart. Five percent 
of emergency department visits with chest pain not relating to myocardial infarction are 
attributed to pericarditis. Evidence shows 80% of cases in developed nations are 
idiopathic or post-viral in nature. Treatment has consisted of NSAIDS and 
glucocorticoids as first line therapy. Colchicine is an anti-inflammatory medication that 
has long been used in the therapy of gout arthritis and other rheumatologic complaints 
worldwide. It has been proposed that the anti-inflammatory profile occurring within 
joints can apply to the pericardium of the heart. The purpose of this study is to evaluate 
how efficacious colchicine is when added to traditional therapy in the treatment of 
pericarditis. 
 
Methods:  An exhaustive search was conducted using Medline-OVID, CINAHL, and 
Pub-Med using keywords: pericarditis and colchicine. Articles with primary data 
evaluating the use of colchicine in treating pericarditis were included. These relevant 
articles were assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) 
 
Results:  Three studies met the inclusion criteria for this systematic review. A 
randomized, double blind, placebo-controlled study investigating colchicine and the 
treatment of pericarditis demonstrated a reduction in recurrence rate, symptom 
persistence, and the need for hospitalization. A second randomized, double blind, 
placebo-controlled study demonstrated a reduction in disease recurrence, symptom 
persistence, and hospitalization related to the disease. Another randomized, open-label 
trial evaluating colchicine therapy in treating acute pericarditis demonstrated a decrease 
in recurrence rate and symptom persistence.  
 
Conclusion: Colchicine when treating pericarditis was demonstrated to reduce disease 
recurrence, lessen symptom persistence, and limit the need for hospitalization. The safety 
and efficacy has been evaluated through multiple trials and deemed superior to standard 
therapy alone. The overall quality of the studies reviewed is moderate based on the 
GRADE criteria. A weak recommendation for the off-label use of colchicine in the 
treatment plan of pericarditis can be given at this time based on the available data. 
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Efficacy of Colchicine When Added to Traditional Anti-inflammatory Therapy in 
the Treatment of Pericarditis 
BACKGROUND 
Pericarditis is the most common disease affecting the pericardium of the heart.1 
The pericardium, a fibrous sac surrounding the myocardium of the heart, can become 
inflamed and irritated by various processes. These include idiopathic, tuberculous, 
neoplastic, or post-traumatic in nature. Greater than 80% of these are of post-viral or 
idiopathic etiology in developed countries.2  
 Pericarditis is said to be recorded 1 out of every 1000 hospitalized patients and 
5% of patients admitted to the emergency department for chest pain not attributed to 
myocardial infarction.3 Males under the age of 50 have demonstrated an increased 
incidence of acquiring pericarditis.4  
Pericarditis is typically a benign disease process overall but necessitates treatment 
to prevent dangerous sequela. Pericardial effusion or fluid surrounding the heart tissue 
within the pericardial sac can lead to cardiac tamponade. Cardiac tamponade and the 
restrictive nature placed on the myocardium results in reduced blood pressure and cardiac 
output requiring emergency action to prevent mortality.2  
Diagnosis is made on the basis of established criteria in previous studies,5 which 
include two of the following: Typical pleuritic chest pain improved with leaning forward, 
pericardial friction rub on auscultation, ST-segment changes on ECG, and new or 
worsening pericardial effusion seen on echocardiogram. Inflammatory markers such as 
elevated white blood cell count, elevated C-reactive protein, or elevated erythrocyte 
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sedimentation rate can help follow progression of the disease but are not solely used for 
diagnostic purposes.6 
 The treatment of pericarditis has been tailored towards idiopathic causation which 
accounts for greater than 80% of cases in developed nations and has long been empirical 
in nature. The first line approach has been aspirin and other NSAIDS such as ibuprofen 
or indomethacin. Glucocorticoid use for patients who are unable to tolerate typical 
NSAIDS has been initiated but proven to increase risk of relapse once the drug is 
tapered.7 Pericardectomy is an option for severe cases of relapsing pericarditis and 
subsequent effusions. This invasive procedure is reserved for those resistant to 
pharmacological treatment including the topic of choice, colchicine.8 
 Colchicine has long been used in the treatment and prevention of gout arthritis 
and related rheumatologic complaints. Originally extracted from the plant Autumn 
Crocus, it was initially described by Ebers Papyrus in 1500 BC. It has since been used in 
medicine over many centuries including today’s label indications for gout and familial 
mediterranean fever.6 Colchicine’s mechanism of action is not fully understood but is 
stated to actively concentrate in WBCs, especially granulocytes, blocking tubulin 
polymerization and microtubules generation. This interferes with several functions of 
these cells including migration, phagocytosis, and degranulation.9 The end result of this 
process is a limitation of a major player in the body’s inflammatory process, cytokine 
interleukin 1-beta.6 
  The medication’s impact on pericardial disease has been pushed to the forefront 
since the mid 90’s and early 2000’s. Currently, a recommendation is made by The Task 
Force on the Diagnosis and Management of Pericardial Diseases of the European Society 
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of Cardiology (level of evidence B, class IIa indication) but as such still remains off 
label.7 The purpose of this study is to explore the therapeutic potential of colchicine in 
treating pericarditis. This review will be primarily looking at outcomes associated with 
symptom duration, recurrence of disease, and hospitalization rate secondary to 
pericarditis. 
 
METHODS 
A comprehensive search of available medical literature was conducted using 
CINAHL, Medline-Ovid, and PubMed using the following keywords: pericarditis and 
colchicine.  The search was then narrowed to studies in the English language, on human 
participants, and conducted as random control trials. The bibliographies of these articles 
were further researched for background information and relevant sources. The relevant 
articles were then assessed for quality using the Grading of Recommendations, 
Assessment, Development and Evaluation. (GRADE)10 Lastly, a search on the National 
Institute of Health (NIH) clinical trials site revealed no currently registered trials, at any 
phase, relating to the use of colchicine in the treatment of pericarditis. 
RESULTS 
The initial search produced 354 articles for review. After screening these relevant 
articles for primary data using the above eligibility criteria, a total of three articles 
remained. These articles included three randomized controlled trials that were conducted 
in Italy by the same researchers.11-13 (see Table 1). 
 
- 9 - 
 
 
 
ICAP Trial 
 The Investigation on Colchicine for Acute Pericarditis trial,11 described by its 
authors is a prospective double blind, placebo-controlled trial. The purpose of the study 
was to investigate the effects of adding colchicine to traditional anti-inflammatory 
therapy in treating acute pericarditis. The primary outcome to be measured was 
pericarditis recurrence. Secondary outcomes included symptom persistence beyond 72 
hours, hospitalizations related to disease, remission rate at 1 week, and adverse effects of 
the therapy.11 
In this study a total of 240 patients were selected from five general hospitals in 
Northern Italy. Two groups were set forth and balanced for prognostic and diagnostic 
characteristics (see Table 2). Eligibility for enrollment was limited to subjects aged at 
least 18 and presenting with their first episode of acute pericarditis. The diagnosis of 
acute pericarditis was made with the following criteria: presentation of typical sharp and 
pleuritic chest pain improved by leaning forward, a pericardial friction rub, widespread 
ST-changes on ECG, or new or worsening pericardial effusion seen on echocardiogram. 
Patients were considered ineligible and therefore excluded if the etiology of pericarditis 
was tuberculous, neoplastic, or purulent. Additionally, they were omitted if subjects had 
known severe liver disease or transaminases >1.5 of normal limit, had CK above 2.5 
mg/dL, had known blood dyscrasias or gastrointestinal disease, were pregnant or 
lactating females, who were women of childbearing age not protected by contraception 
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methods, who are undergoing colchicine therapy for any other known reason, or who 
have known sensitivity to the drug.11 
 Once proven to be eligible, patients were randomly assigned to one of two 
treatment groups by way of a central computer-based automated sequence. 
Randomization was based on permuted blocks of four. The random assignment was 
enacted with the use of sequentially numbered drug containers. All participants received 
conventional treatment for acute pericarditis which included 800mg of aspirin or 600mg 
of ibuprofen orally every 8 hours for 7-10 days; followed by tapering over 3-4 weeks. 
Glucocorticoids (prednisone 0.2-0.5mg/kg) were used in those with absolute 
contraindication to NSAIDS such as allergy, history of peptic ulcer disease or 
gastrointestinal bleed, and current oral anticoagulation whose bleeding risk was 
considered high. All patients received an undisclosed PPI for prophylaxis.  Patients 
allocated to receive colchicine were given a dose of 0.5 mg to 1.0 mg day for 3 months. 
This dosing was previously established from safety measures in the COPE trial.12 The 
lower dose (0.5mg BID) was reserved for those weighing less than 70kg. The placebos 
were indistinguishable in color, shape, and taste as well as being scored so that it is 
identical to the colchicine tablets for lower dosing.11  
 The enrollment period began in August 2005 and ended in December 2010. 
Follow-up continued through June 2012. Outcomes were measured for a minimum of 18 
months, with an average of 22 months. Regular visits were established at 1 week, 1 
month, 3 months, 6 months, 1 year, and 18 months. Each visit consisted of blood work 
(CBC, C-reactive protein, aminotransferase), ECG, and echocardiogram. A clinical 
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endpoint committee who was unaware of group assignment adjudicated each clinical 
endpoint.11 
 Of the 120 patients who received colchicine as part of their therapy, the primary 
outcome of recurrent pericarditis occurred 11/120 vs 25/120 in the placebo group (RR: 
0.43, NNT: 9, p=0.02). The secondary endpoints of symptom persistence greater than 72 
hours occurred 23/120 patients who received colchicine and 48/120 in those who 
received traditional therapy plus placebo (RR: 0.40, NNT: 5, p=0.001). Lastly, the 
outcome of hospitalization occurred 6/120 in the colchicine group and 17/120 in the 
placebo group (RR: 0.35, NNT: 11, p=0.02). In the ICAP trial, there were 11 out of 120 
subjects having gastrointestinal intolerances to colchicine compared to 10 out of 120 
patients in the placebo group. Complete follow-up was accomplished in 106/120 patients 
in the colchicine group and 108/120 in the placebo group. The most frequent adverse 
effect to cause discontinuation being gastrointestinal intolerance. 11 
 The authors concluded colchicine reliably reduced the rate of recurrence in 
pericarditis, effectively lessened symptom persistence longer than 72 hours, and limited 
the need for disease-related hospitalization. It was proven to be a safe and reliable 
adjunctive therapy in the treatment of pericarditis. 
 The authors acknowledged limitations within the study. First, the study may not 
be generalized to other clinical conditions or populations secondary to the extensive 
exclusion criteria. Second, the use of colchicine is currently off label and not approved 
for the prevention of recurrent pericarditis in North America or Europe. Finally, they note 
a small sample size that may preclude certain adverse effects. The researchers 
recommend further research into proper colchicine duration of therapy.11  
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COPE Trial 
 The Colchicine for Acute Pericarditis (COPE) trial12 is described by its authors as 
a prospective, randomized, open label design. The intent of the study was to evaluate the 
efficacy of colchicine when added to conventional anti-inflammatory therapy in the 
treatment of acute pericarditis. The primary outcome measured was recurrence rate of 
pericarditis after treatment. Secondary outcomes included symptom persistence and 
adverse effects of therapy. The study was approved by the institutional review board.12  
 In this study, a total of 120 patients selected from two Italian medical centers 
were randomly assigned to one of two groups. They were balanced for prognostic and 
demographic quality (see Table 3). Eligibility for enrollment was limited to patients with 
a first episode of acute pericarditis defined by at least two of the following: typical chest 
pain, pericardial friction rub, and widespread ST- segment changes on ECG. In addition, 
subjects were limited to those of ages 18 or older, pericarditis of (idiopathic, viral, 
autoimmune causes, PPS, connective tissue disease), and those who gave informed 
consent. Patients were excluded if the etiology of pericarditis was tuberculous, neoplastic, 
or purulent. Additionally, they were omitted if subjects had known severe liver disease or 
transaminases >1.5 of normal limit, had CK above 2.5 mg/dL, had known blood 
dyscrasias or gastrointestinal disease, were pregnant or lactating females, who were 
women of childbearing age not protected by contraception methods, those who are 
undergoing colchicine therapy for any other known reason, or who have a known 
sensitivity to the drug.12 
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 The two randomly assigned treatment groups were to receive conventional 
therapy with aspirin 800mg orally every 6-8 hours for 7 to 10 days with tapering over 3-4 
weeks alone (group 1) or combined with colchicine 1.0-2.0 mg on day 1 and then 
maintenance dosing of 0.5-1.0 mg daily for 3 months.(group 2). The lower maintenance 
dose of 0.5 mg was reserved for those <70kg in the study.  Both groups received 
omeprazole 20mg/day for gastrointestinal prophylaxis. Prednisone replaced aspirin at a 
dose of 1.0-1.5 mg/kg/day for 2-4 weeks for those with absolute contraindication to 
aspirin such as allergy or elevated bleeding risk.12 
 Between the enrollment period of January 2002 and August 2004, 120 patients 
were entered into the study. After randomization was complete using permuted blocks of 
four, follow-up visits were conducted at the following intervals: 48 hrs, 72 hrs, 10 days, 1 
month, 3 months, 6 months, 1 year, and yearly for cases of uncomplicated nature. The 
average time for follow up was 23.7 months for the control group and 24.2 months in the 
colchicine group. Complete follow-up was accomplished in 55/60 patients in the 
colchicine group with five patients lost secondary to discontinuation due to diarrhea. No 
subjects within the control group were lost to follow-up. Each clinical event was ensured 
by an ad-hoc committee of expert cardiologist blinded to patient’s treatment assignment. 
The data analyses were performed by external committee which was blinded to treatment 
subgroups.12 
 With regards to the primary outcome, recurrence rate of pericarditis at 18 months, 
colchicine was shown to be superior to the control group of ASA/Glucocorticoid therapy 
alone. Recurrence of pericarditis occurred in 7/60 patients within the colchicine therapy 
group vs. 20/60 patients in the control group (RR 0.35, NNT 5, p=0.004).12The secondary 
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outcome of symptom persistence of 72 hours in duration was similarly lessened in the 
colchicine group. Symptoms persisted in 7/60 patients within the colchicine group and 
22/60 in the control group (RR 0.32, NNT 4, p=0.003). According to the researchers of 
this study, therapy was generally well tolerated in both groups. There were five reported 
cases of diarrhea within the colchicine therapy group; causing discontinuation of the drug 
and prompt reversal of symptoms. There were no participants who acquired 
gastrointestinal intolerance leading to the withdrawal from the control group12 
 The authors concluded that colchicine in combination with traditional therapy 
such as aspirin was efficacious and safe in the treatment of pericarditis. They noted 
however, the limitations of the study center around the open label design, which allows 
for bias to enter into the equation by both the prescribing doctor and the patient. There 
was an attempt to minimize the effect with a blinded ad hoc committee overseeing 
outcome events and an independent data analyses committee blinded to assignment. 
Never the less, a double-blind study would eliminate all cause for concern.12  
 
CORP Trial 
 The Colchicine for Recurrent Pericarditis (CORP) trial 13 is described by the 
authors as a prospective, randomized, double-blind, placebo-controlled multicenter 
design. The intent of this study was to evaluate the efficacy and safety of colchicine for 
the secondary prevention of recurrent pericarditis. The primary outcome set forth was 
recurrence rate at 18 months. Secondary endpoints included symptom persistence at 72 
hours, disease-related hospitalization, remission rate at 1 week, number of recurrences, 
time to first recurrence, and cardiac tamponade. 13 
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 In the study, a total of 120 patients were selected from four general hospitals in 
Italy (Maria Vittoria Hospital, Ospedali Riuniti, San Maurizio Regional Hospital, and 
Ospedale SS Annunziata). They were balanced for prognostic and diagnostic quality (see 
Table 4).13 Eligibility for enrollment was limited to patients with a first recurrence of 
pericarditis. Pericarditis was established by having two of the following criteria: typical 
pericardial chest pain, pericardial friction rub, widespread ST changes on ECG, and new 
or worsening pericardial effusion seen on echocardiogram. Participants in additional 
needed to be 18 years of age or older and provide informed consent. Patients were 
excluded if they were having first episode of acute pericarditis, pericarditis with etiology 
that was tuberculous, neoplastic, or purulent. Subjects were additionally precluded with 
known severe liver disease or transaminases >1.5 of normal limit, had CK above 2.5 
mg/dL, had known blood dyscrasias or gastrointestinal disease, were pregnant or 
lactating females, who were women of childbearing age not protected by contraception 
methods, and those who are undergoing colchicine therapy for any other indication.13  
 Participants were randomly assigned to one of two groups by a central computer-
based automated sequence based on permuted block sizes of four.  Random allocation 
sequence was implemented by using sequentially numbered containers. All participants 
and investigators were blinded to assignment. Unblinded data was made available to an 
independent data and safety and monitoring board in the event of side effects. The data 
was collected by using case report and clinical events adjudication forms which were 
managed by a blinded committee. An end point committee oversaw clinical endpoints 
and was blinded to assignment as well.13 
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 All patients in both the control and experimental group received conventional 
therapy in the form of aspirin 800-1000 mg (or ibuprofen 600 mg) orally every 8 hours 
for 7-10 days with a gradual taper of 3-4 weeks. Prednisone in a dosing of 0.2-0.5 
mg/kg/day for four weeks followed by a similar taper was given to those with absolute 
contraindication to NSAIDS such as allergy, history of peptic ulcer, gastrointestinal 
bleed, or high risk of bleeding due to oral anticoagulation. Every patient who received 
either aspirin or ibuprofen received a PPI for prophylaxis.13 
The experimental group was additionally given colchicine 1.0-2.0 mg on day one, 
followed by maintenance of 0.5-1.0mg/day for six months. All doses were given every 12 
hours. The lower dosing of 0.5 mg/day was implemented for those who weighed less than 
70 kg or were unable to tolerate the higher dose of 1.0 mg/day. Placebo tablets were 
identical in shape, color, and taste. 13 
 The enrollment period proceeded from August 2005 to April 2009 with the trial 
completed in October 2010, which was at the 18 month follow up for the last enrolled 
patient. Once each subject was allocated to the treatment or control group, follow-up 
visits were conducted at the following intervals: 1 week, 1 month, 3 months, 6 months, 
12 months, and 18 months. Each visit consisted of echocardiogram, blood chemistry, 
complete blood count, C-reactive protein, creatinine, and aminotransferase levels. During 
the follow up, adverse events were monitored by the above mentioned independent safety 
committee. Lost to follow-up but not analysis were 5/60 in the colchicine group and 4/60 
in the placebo group. This was reportedly due to gastrointestinal discomfort (see Table 
5).11-13 
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 The primary outcome of pericarditis recurrence rate at 18 months was 
demonstrated to be superiorly improved with the addition of colchicine to the traditional 
therapy of NSAIDS or glucocorticoids. The recurrence rate within the colchicine group 
was effectively 14/60 and the placebo group was 33/60 (RR: 0.42, NNT: 4, p=<0.001). 
Additionally, colchicine showed to benefit symptom persistence beyond 72 hours at a 
rate of 13/60 vs. the placebo group’s 33/60 (RR: 0.42, NNT: 4, p=0.001). Hospitalization 
related to disease was lessened as well with the colchicine group having 3/60 and the 
placebo group attaining 8/60 hospitalized subjects (RR: 0.38, NNT: 12, p=0.20). The 
most frequently adverse effect was GI discomfort (see Table 5). This was reversed 
promptly with lowering the dose of colchicine or ultimately withdrawing the medication 
by the investigators. Overall, 4 out of 60 patients reported gastrointestinal side effects in 
the colchicine group and 3 out of 60 patients obtained gastrointestinal intolerance 
issues.13 
  The authors concluded colchicine halved the recurrence rate at 18 months, 
hastened symptom resolution, and limited hospitalization while maintaining a high level 
of tolerability. The addition of colchicine to traditional anti-inflammatory regiment was 
safe and efficacious.13 
The authors did acknowledge study limitations as such the exclusion criteria were 
extensive and were only applicable to adults. A significant road block echoed by the 
authors is that, currently, the use of colchicine in the treatment of pericarditis is not 
approved in North America or Europe, and that the use is off-label.13  
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DISCUSSION 
Clinical Relevance 
 The general approach in the treatment of pericarditis has been well established in 
literature. NSAIDs and glucocorticoids are still the mainstay of therapy and 
recommended in the only guidelines available on the treatment pericarditis.7 However, a 
consideration for colchicine administered as adjunctive therapy should be considered due 
to the above research  
Colchicine has proven to be both safe and efficacious when added to conventional 
therapy in the treatment of pericarditis. To date, the reviewed RCTs11-13  have produced 
promising results regarding the benefit of treating patients with colchicine in addition to 
traditional pericardial anti-inflammatory therapy.  All three clinical trials conducted by 
Imazio et al11-13determined that the use of colchicine was superior in minimizing 
symptom persistence, stalling recurrence of disease, and limiting hospitalizations due to 
pericarditis. While classified officially as an “off-label” indication in the therapy of 
pericarditis, evidence is being brought to the forefront for the safety and effectiveness 
when added to traditional treatment regiments.  
Efficacy and safety profiles in addition to developing a standardized dosing of 
colchicine have given the taskforce for European Society of Cardiology confidence to 
include it in their guidelines.7 However, there is still some question as to the duration of 
therapy. The above studies treated patients for 3-6 months. Moreover, one must take into 
consideration the patient at hand and the specific etiology of pericarditis. 
When specifically addressing the safety of colchicine in patients with acute 
pericarditis, research is lacking. A brief overview of adverse events in each of the three 
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trials is available found in Table 5. 11-13However, the safety profile is well established in 
patients with gout. It is well known that gastrointestinal upset including diarrhea, 
vomiting and nausea, are the main side effects of colchicine. This has been effectively 
reduced by lowering the effective dose or adding prophylaxis with a proton pump 
inhibitor.  
The individual circumstance of your patient including renal and liver function 
must meet requirements in order to be considered safe for therapy. Colchicine is 
eliminated primarily via hepatic metabolism by the Cytochrome P450 (CYP) system. It is 
interference with this system that potentially causes toxicity from colchicine. Any 
medications that interact with the CYP system or those that inhibit P-glycoprotein have 
the potential to increase colchicine’s exposure by slowing down elimination. Some of 
these commonly prescribed medications include digoxin and macrolide antibiotics.9 
Colchicine's half-life is doubled in patients with renal failure and by 10 times in the 
presence of liver cirrhosis.6 These facts contributed to the exclusion criteria focused on 
liver and renal disease noted in all three trials.11-13  
The last concern is cost. The cost of colchicine is currently at $4.85 a tablet (0.6 
mg tablet) since 2009 when the FDA granted sole exclusivity to URL-Pharma.14 Prior to 
this change it was 9 cents per pill as a generic medication.  Factoring in these 
considerations while meeting criteria laid down through prior research,11-13 we can treat 
safely and appropriately with colchicine for pericarditis. 
Limitations of studies 
While every study demonstrated an added benefit and minimal harm in the 
addition of colchicine as seen in the summary of findings table (see Table 1)11-13 the 
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studies are not without limitations. The ICAP trial11 showed us that while specific causes 
of pericarditis can successfully be treated with colchicine, it excluded various other 
etiologies of the disease including bacterial and neoplastic. The applicability to a more 
general population contracting this disease is minimized as evidence shows us that 
outside of developed countries, tuberculous and bacterial etiology is of common 
occurrence.15 The COPE trial12 lacked concealment or blinding allowing each participant 
and investigator knowledge of who was receiving colchicine therapy. This damages the 
validity of the results in any study and can be easily remedied with appropriate study 
design adjustments. The CORP trial,13 while again proving that colchicine has its place 
amongst the therapy of pericarditis, demonstrated flaws. Similar to those before it, a cross 
application to bacterial pericarditis cannot be achieved. Research to further apply 
colchicine in this arena is needed and recommended by its authors. 
Overall, the lack of experimental trials conducted by others practicing outside of 
the Italian Cardiology community is disconcerting.  Dr. Immazio has been well 
established as a leading expert in the field of pericardiology, but further diverse 
investigations need to be obtained. The geographical limitations set forth by selection of 
participants in the Italian Health System show mild cause for concern in the true 
effectiveness of colchicine. The Mediterranean part of the world is privy to isolated 
familial disease including familial mediterranean fever. FMF is treated with colchicine as 
well.16 The possibility that each study’s sampling location skews the results secondary to 
a perceived advantage when colchicine is used.  
Currently there is a systematic review17 conducted by Dr. Imazio regarding his 
own work including the COPE and CORP trials as well as study by Finkelstein regarding 
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pericarditis.18 The objectivity of a systematic review on one’s own studies seems a 
difficult task to maintain. The question needed addressing and an independent review of 
whether the included trials12, 13 were of high quality was initiated. This review in 
addition, included Dr. Imazio’s newest trial11 published in the New England Journal of 
Medicine which was not originally incorporated in his systematic review. 
To fully assess for bias or limitations in design, all three RCTs were evaluated 
using the GRADE protocol. The outcomes of pericarditis recurrence and symptom 
persistence were investigated by all three studies,11-13 while only two of the three 
examined hospitalization rate.11, 13 All three studies being RCTs began with a GRADE of 
high. With regards to all three primary outcomes, the overall GRADE was moderate, 
related to the high risk of publication bias.  
CONCLUSION 
 Colchicine has been demonstrated to be a valuable adjunctive therapeutic option 
when treating pericarditis. More specifically is has shown to reduce the rate of recurrent 
pericarditis, limit symptom persistence, and lower hospitalization rate secondary to the 
disease. It has been used for decades in medicine but only recent has been making a case 
for being included in the therapy for pericarditis. The overall qualities of the studies 
reviewed were moderate based on the GRADE criteria. A weak recommendation for the 
use of colchicine in the therapy of pericarditis can be made based on quality of evidence. 
Further research and randomized control studies evaluating colchicine as mono-therapy 
for pericarditis are needed to determine independent efficacy and work towards achieving 
on-label approval for pericarditis management. 
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Table 1 GRADE evidence profile: Colchicine and the treatment of pericarditis 
 
GRADE: Grading of Recommendations, Assessments, Development and Evaluation. 
a,COPE Trial: The COPE trial was an open label study however the other two studies had strong allocation concealment therefore no downgrade necessary. 
b All studies were conducted by the same researchers 
 
Quality Assessment Summary of Findings 
 Downgrade Criteria  Number of Patients Effect 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
Bias 
Study 
Colchicine 
added 
Placebo or no 
Colchicine 
 
Relative 
Risk 
NNT/NNH 
Quality 
Importance 
Recurrence of Pericarditis 
ICAP11 
11/120 25/120 0.43 
NNT 
9 
COPE12 
7/60 20/60 0.35 
NNT 
5 
3 
 
3 RCT 
 
No serious 
limitationa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Publication bias is 
likelyb 
CORP13 
14/60 33/60 0.42 
NNT 
4 
Moderate Important 
Symptom persistence >72 hours 
ICAP11 
23/120 48/120 0.40 
NNT 
5 
COPE12 
7/60 22/60 0.32 
NNT 
4 3 
3 RCT 
 
No serious 
limitationa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Publication bias is 
likelyb 
CORP13 
 
13/60 31/60 0.42 
NNT 
4 
Moderate Important 
Hospitalization related to disease 
ICAP11 
6/120 17/120 0.35 
NNT 
11 
2 
2 RCT 
 
No serious 
limitation  
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Publication bias is 
likelyb CORP13 
3/60 8/60 0.38 
NNT 
12 
Moderate Critical 
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Table 2: ICAP trial patient characteristics at Baseline 
Characteristics Placebo 
(N=120) 
Colchicine 
(N=120) 
   
Age (Mean) 50.7+/- 17.5 53.5+/- 16.2 
Male Gender # 74 71 
Causes of Pericarditis 
  
Idiopathic 93 92 
Autoimmunea 4 3 
Clinical Findings 
  
Pericardial Chest pain 119 120 
Pericardial Rub  38 44 
ST Elevation on ECG 26 35 
Pericardial effusion 84 76 
Total Subjects in each group N=120 N=120 
Source: ICAP11 
aAutoimmune includes those with connective tissue etiology. 
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Table 3: COPE trial patient characteristics at Baseline 
Characteristics No Colchicine 
(N=60) 
Colchicine 
(N=60) 
   
Age (Mean) 57.2 +/- 19.6 56.5+/- 18.2 
Male Gender # 26 28 
Causes of Pericarditis 
  
Idiopathic 51 50 
Autoimmuneb 9 10 
Clinical Findings 
  
Pericardial Chest pain 60 60 
Pericardial Rub  19 21 
ST Elevation on ECG 53 52 
Pericardial effusion 38 41 
Total Subjects in each group N=60 N=60 
Source: COPE12 
bAutoimmune includes those with connective tissue etiology 
 
 
 
 
 
 
 
 
 
Table 4: CORP trial patient characteristics at Baseline 
Characteristics Placebo Colchicine 
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(N=60) (N=60) 
   
Age (Mean) 47.3+/- 14.4 47.9+/- 15.4 
Male Gender # 29 34 
Causes of Pericarditis 
  
Idiopathic 48 50 
Autoimmunec 12 10 
Clinical Findings 
  
Pericardial Chest pain 60 60 
Pericardial Rub  13 12 
ST Elevation on ECG Not Included Not Included 
Pericardial effusion 35 36 
Total Subjects in each group N=60 N=60 
Source: CORP13 
cAutoimmune includes those with connective tissue etiology 
 
 
 
 
 
 
 
 
 
Table 5: Subjects with adverse events 
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ICAP COPE CORP 
 
Colchicine 
group 
Placebo Colchicine 
group 
Anti-
inflammatory 
alone 
Colchicine 
group 
Placebo 
GI Intolerancea 11  
(9.2%) 
10 
(8.3%) 
5 
(8.3%) 
4 
(6.6%) 
4 
(6.6%) 
3 
(5.0%) 
Hepatotoxicity 2 
(1.6%) 
1 
(.83%) 
NS NS 0 
(0%) 
1 
(.83%) 
Subjects 
withdrawn 
from study 
14 
(11.7%) 
10 
(8.3%) 
5 
(8.3%) 
0 
(0%) 
5b 
(8.3%) 
4 
(6.6%) 
Total 
participants 
analyzed 
N=120 N=120 N=60 N=60 N=60 N=60 
 
Source: ICAP, COPE, CORP trials11-13 
a Includes diarrhea, nausea, vomiting, abdominal pain 
b One additional patient withdrew self from study without cause or adverse event 
